Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Trial Profile

Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Ocular inflammation; Ocular pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 26 Sep 2014 Primary endpoint of 'complete resolution of eye pain by day eight' has been met, according to a Bausch + Lomb media release.
    • 26 Sep 2014 Top-line results published in Bausch + Lomb media release.
    • 26 Sep 2014 According to a Bausch + Lomb media release, full results will be presented at a future ophthalmic congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top